| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to new compounds of formula (I) , where Z means where R means hydrogen, C 4 -C 6 cycloalkyl group attached either through one of ring carbon atoms, or through a lower alkylene group attached to the ring, or a linearly chained or branched lower alkyl group or a lower hydroxyalkyl group, or a lower aminoalkyl group, or a phenyl(lower alkyl) group optionally substituted with 1-2 substitutes chosen from lower alkyl, lower alkoxy, halogen and hydroxy, or heteroaryl(lower alkyl)group where heteroaryl is chosen from the group consisting from thienyl, substituted with lower alkyl group, imidazolyl, and thiazolyl substituted with the lower alkyl group; n means 0 or 1; or Z means a group where R means the lower alkyl group; X 1 means methylene or NH group; and X 2 means methylene; or X 1 means methylene and X 2 means methylene or a bond; or X 1 means methylene, and X 2 means O, S or a bond; Y 1 means methylene, and Y 2 means methylene, vinylene, ethylene, or a bond; Ar 1 means unsubstituted or substituted phenyl; Ar 2 means unsubstituted or substituted phenyl, unsubstituted or substituted thienyl, unsubstituted or substituted furyl, unsubstituted or substituted pyridyl; and when Ar 1 and Ar 2 are substituted, each Ar 1 and Ar 2 are independently substituted with one or more substituted chosen from lower alkyl, lower alkoxy, hydroxy, lower hydroxyalkyl, halogen, di- and trihaloalkyl, di- and trihaloalkoxy, mono- and dialkylamino, alkilthio, alkyl ester and nitro; provided that Ar 1 and Ar 2 do not simultaneously mean unsubstituted phenyl; W means oxygen or sulphur; or to their pharmaceutically acceptable salts; provided those specified in cl. 1 of the patent claim. Besides the invention concerns the compounds chosen from the group, to compounds of formula (I), to pharmaceutical compositions, to a method of inhibition of monoamine receptor activity, to a method of inhibition of monoamine receptor activation, to a method of treating a diseased state associated with serotonin receptor, to a method of treating schizophrenia, to a method of treating migraine, and also to a method of treating psychosis. n EFFECT: preparation of the new biologically active compounds capable to inhibit monoamine receptor activity. n 65 cl, 140 ex, 5 tbl |